Please check your internet connection and try again.
### Pantoprazole
#### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
#### Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
* H. pylori eradication (in combination therapy)
#### Adult Dosing
* **GERD & Erosive Esophagitis:** 40 mg once daily. Duration of treatment varies.
* **Pathological Hypersecretory Conditions:** Starting dose typically 40 mg twice daily, may be increased as needed. Maximum dose is generally 120 mg per day divided into two doses.
* **H. pylori Eradication:** 40 mg twice daily in combination with antibiotics.
#### Pediatric Dosing
* **GERD & Erosive Esophagitis (5 years and older):** 20 mg once daily for erosive esophagitis, 10-40 mg once daily for GERD. Dosing is weight-based for some indications. Consult specific pediatric guidelines.
#### Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 40 mg once daily.
* **Renal Impairment:** No dose adjustment necessary.
#### Contraindications
* Hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
#### Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
* **Serious:**
* **Long-term use:** Increased risk of Clostridium difficile infection, bone fractures (hip, wrist, spine), vitamin B12 deficiency, hypomagnesemia (potentially severe).
* **Acute Interstitial Nephritis**
* **Fundic gland polyps**
#### Key Drug Interactions
* **Drugs affected by gastric pH:** Decreased absorption of drugs requiring acidic environment (e.g., ketoconazole, itraconazole, dasatinib, nelfinavir).
* **CYP2C19 substrates:** Potential for interactions, though generally considered less than omeprazole or esomeprazole.
* **Methotrexate:** Increased methotrexate levels with PPIs.
#### Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias), vitamin B12 deficiency, and bone fractures with long-term use.
* Monitor for diarrhea suggestive of C. difficile infection.
#### Clinical Pearls
* Pantoprazole is generally less likely to inhibit CYP2C19 compared to other PPIs, potentially leading to fewer drug interactions with CYP2C19 substrates.
* Administer 30 minutes before a meal.
* IV formulation available for patients unable to take oral medication.
* Short-term use is preferred. Consider step-down therapy or discontinuation when clinically appropriate.
***
*Disclaimer: This information is for educational purposes only and does not substitute for professional medical advice. Always consult the most current prescribing information and guidelines for definitive patient care.*
